Response of High-Risk MDS to Azacitidine and Lenalidomide is Impacted by Baseline and Acquired Mutations in a Cluster of Three Inositide-Specific Genes
Author
McCubrey, James A.
Date
2019-09
Citation:
APA:
McCubrey, James A.. (September 2019).
Response of High-Risk MDS to Azacitidine and Lenalidomide is Impacted by Baseline and Acquired Mutations in a Cluster of Three Inositide-Specific Genes.
Leukemia,
(33:9), p.2276-2290. Retrieved from
http://hdl.handle.net/10342/9631
MLA:
McCubrey, James A..
"Response of High-Risk MDS to Azacitidine and Lenalidomide is Impacted by Baseline and Acquired Mutations in a Cluster of Three Inositide-Specific Genes". Leukemia.
33:9. (2276-2290.),
September 2019.
May 20, 2022.
http://hdl.handle.net/10342/9631.
Chicago:
McCubrey, James A.,
"Response of High-Risk MDS to Azacitidine and Lenalidomide is Impacted by Baseline and Acquired Mutations in a Cluster of Three Inositide-Specific Genes," Leukemia 33, no.
9 (September 2019),
http://hdl.handle.net/10342/9631 (accessed
May 20, 2022).
AMA:
McCubrey, James A..
Response of High-Risk MDS to Azacitidine and Lenalidomide is Impacted by Baseline and Acquired Mutations in a Cluster of Three Inositide-Specific Genes. Leukemia.
September 2019;
33(9)
2276-2290. http://hdl.handle.net/10342/9631. Accessed
May 20, 2022.
Collections